Denver, Colorado- U.S. equity markets are finding their footing this morning as investors digest a wave of company-specific developments that highlight a recurring theme for 2026: real infrastructure is beginning to converge with scalable execution. From enterprise-grade tokenization and biotech de-risking to additive manufacturing in orbit and grid-scale energy storage, several names are shaping a narrative that extends beyond short-term trading and into structural opportunity.
VerifyMe (NASDAQ:VRME): From Logistics to On-Chain Trust Infrastructure
VerifyMe is in focus following its announcement of a letter of intent to merge with Open World Ltd., a major behind-the-scenes force in the Web3 ecosystem. Upon completion, the combined company is expected to remain publicly traded on Nasdaq under a new ticker symbol, with Open World shareholders projected to own approximately 90% of the merged entity.
Strategically, the merger aims to fuse VerifyMe’s precision logistics, authentication, and anti-counterfeit technologies with Open World’s enterprise-grade blockchain infrastructure and real-world asset (RWA) tokenization expertise. The result is intended to be a compliance-ready platform designed for institutional adoption, addressing core barriers to digital asset scale: identity, provenance, regulatory alignment, and trust.
The announcement follows Open World’s recent partnership with Abstract to develop a national-scale, compliant tokenization engine for infrastructure-grade RWAs, signaling momentum toward production-level deployment rather than experimentation. With due diligence underway during a 60-day exclusivity period, the transaction underscores how legacy verification technologies are increasingly being repositioned as foundational layers for the agentic AI and tokenized economy.
Kraig Biocraft Laboratories (OTCQB:KBLB): From Breakthrough Science to Early Commercialization
Kraig Biocraft Laboratories enters 2026 with growing attention after recently publishing a detailed shareholder letter outlining material scientific, production, and commercialization progress. The company highlighted a year of breakthroughs in recombinant spider silk, including record-setting gene insertions, the development of Darwin Bark Spider and Caddis Fly silks, and the rollout of its BAM-1 ALPHA hybrid, which delivers a reported 22% yield improvement over prior strains.
Operationally, Kraig Labs expanded into parallel manufacturing facilities and secured operating licenses and strategic government collaborations across Southeast Asia, diversifying production risk and increasing scalability. Importantly, 2025 marked the company’s transition from development to commercialization, with its first commercial trial order secured in November.
As Kraig Labs heads into 2026 with over one million ALPHA eggs produced and ready for deployment, the narrative is shifting from scientific promise to execution and revenue potential across performance apparel, equipment, and luxury materials.
RedHill Biopharma (NASDAQ:RDHL): Targeting a Hidden Bottleneck in the GLP-1 Boom
RedHill Biopharma is advancing RHB-102 (Bekinda®) across multiple gastrointestinal indications, with particular investor focus on its potential role in addressing GLP-1 and GIP therapy–related GI side effects, a leading cause of discontinuation for blockbuster diabetes and weight-loss drugs.
RHB-102 is a once-daily, extended-release oral formulation of ondansetron supported by positive U.S. Phase 3 and Phase 2 data in gastroenteritis and IBS-D, decades of real-world clinical use, and a planned accelerated FDA 505(b)(2) pathway. RedHill is preparing a Phase 2 proof-of-concept study targeting GLP-1-associated nausea, vomiting, and diarrhea—side effects estimated to drive up to 50% of early therapy discontinuations.
With GLP-1 adoption exceeding 2% of the U.S. population and discontinuation risk potentially eroding tens of billions in forecasted market value by 2030, RedHill’s strategy positions RHB-102 as a potential enabler of sustained therapy adherence across oncology support, GI disease, and metabolic care.
Datavault AI (NASDAQ:DVLT): Taking Tokenization to the Edge—at National Scale
Datavault AI is drawing attention after announcing a nationwide planned deployment across 100 U.S. cities in partnership with Available Infrastructure. The initiative pairs Datavault’s patented DataValue®, DataScore®, and Information Data Exchange® (IDE®) platforms with Available Infrastructure’s SanQtum™ quantum-ready, zero-trust edge computing architecture.
The goal: enable near-real-time tokenization, secure data exchange, and agentic monetization of real-world assets closer to where data is generated. Initial systems integration will begin in 33 major U.S. cities, forming the backbone for Datavault AI’s upcoming exchanges focused on RWAs, NIL, and political data markets expected to launch in early 2026.
By anchoring digital twins, identity, and provenance at the network edge—and securing them with quantum key encryption—the company is positioning itself as an infrastructure provider rather than a speculative Web3 application.
Momentus (NASDAQ:MNTS): Additive Manufacturing Heads to Orbit
Momentus announced the development of an additively manufactured fuel tank, produced with strategic partner Velo3D, scheduled for flight testing aboard the upcoming Vigoride-7 mission. The tank demonstrates how advanced metal 3D printing can reduce lead times, lower costs, and enable complex geometries not feasible with traditional manufacturing.
Momentus plans to leverage this capability to enter new markets as a qualified supplier of space-rated fuel tanks, components historically associated with long timelines and high costs. The milestone reflects a broader shift toward vertically integrated, agile manufacturing in commercial space infrastructure.
SolarMax Technology (NASDAQ:SMXT): Utility-Scale Storage Delivers Revenue Visibility
SolarMax Technology closed the morning with one of the most concrete announcements on the tape: $158.3 million in EPC contracts for two utility-scale battery energy storage projects totaling 400 MWh in Puerto Rico. The projects, located in Humacao and Ceiba, are designed to support grid stability and peak-demand management, while aligning with the island’s clean energy transition.
Beyond EPC revenue through 2027, SolarMax is also acquiring a 9% equity stake in each project, further aligning long-term value creation with operational execution. The contracts strengthen SolarMax’s positioning as a meaningful participant in the rapidly expanding utility-scale energy storage market.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.
For more information, please visit: www.kraiglabs.com
Contact [email protected] for Analyst Report coverage and other investor/public relations services.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated for providing ongoing KBLB market outreach and other services. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimers https://www.247marketnews.com/disclaimer/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
